chevron_leftBack
As of 13 June 2026, 60 Degrees Pharmaceuticals, Inc. has a market cap of $4.19M USD, ranking #45110 globally and #5732 in the United States.
It ranks #3996 in the Healthcare sector, and #786 in the Biotechnology industry.
Key Stats
Market Cap
$4.19MUSD
Enterprise Value
$1.57MUSD
Revenue (TTM)
$1.41MUSD
EBITDA (TTM)
-$7.68MUSD
Net Income (TTM)
-$7.87MUSD
PS Ratio
3.0
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Geoffrey Dow
open_in_new
Employees
3
Founded
2010
IPO
12 Jul 2023
Website
60degreespharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.7% | -9.2% | 5.3% | -70% | -72% | -86% |
News
Loading...
SXTP Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SXTP
ISIN: US83006G5009
Shares Out.:
Shares Outstanding:
2.659M1
Shares Float:
2.635M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.59 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
4M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
4M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
659K%
|
-
|
|
NYSE: IQV
|
$26.3B
628K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
597K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
433K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
1M%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
1M%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
1M%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
1M%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
671K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
613K%
|
-
|
chevron_leftBack